PROK Key Statistics, Chart & Performance
The current stock price of PROK is 2.23 USD. In the past month the price decreased by -9.35%. In the past year, price increased by 19.89%.
PROK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About PROK
Company Profile
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Company Info
PROKIDNEY CORP
2000 Frontis Plaza Blvd, Suite 250
Winston-Salem NORTH CAROLINA US
Employees: 204
Phone: 13369997028
PROKIDNEY CORP / PROK FAQ
What does PROKIDNEY CORP do?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
What is the stock price of PROKIDNEY CORP today?
The current stock price of PROK is 2.23 USD. The price decreased by -0.45% in the last trading session.
Does PROK stock pay dividends?
PROK does not pay a dividend.
What is the ChartMill rating of PROKIDNEY CORP stock?
PROK has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for PROKIDNEY CORP?
PROKIDNEY CORP (PROK) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for PROKIDNEY CORP?
PROKIDNEY CORP (PROK) has a market capitalization of 670.85M USD. This makes PROK a Small Cap stock.
Can you provide the upcoming earnings date for PROKIDNEY CORP?
PROKIDNEY CORP (PROK) will report earnings on 2026-03-13, after the market close.
PROK Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PROK. When comparing the yearly performance of all stocks, PROK turns out to be only a medium performer in the overall market: it outperformed 45.97% of all stocks.
PROK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PROK. While PROK seems to be doing ok healthwise, there are quite some concerns on its profitability.
PROK Financial Highlights
Over the last trailing twelve months PROK reported a non-GAAP Earnings per Share(EPS) of -0.55.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PROK Forecast & Estimates
14 analysts have analysed PROK and the average price target is 6.85 USD. This implies a price increase of 207.11% is expected in the next year compared to the current price of 2.23.